Orthofix Medical Q3 2026: A Profit Miss That Forced a Guidance Cut

Orthofix Medical reported a GAAP loss of $0.15 per share for the third quarter of 2026, missing a consensus estimate of $0.11 profit. That gap reflects several one-time charges embedded in the GAAP result, including share-based compensation, employee transition costs, and acquisition-related fair value adjustments, among others. The company did report adjusted net income but did not disclose an adjusted per-share figure.

The top line also fell short. Net sales of $207.86 million grew 1.1% year over year but missed the $210.52 million analysts had anticipated. The primary drag was U.S. Spine, where revenue fell 4.3% on supplier delays, instrument-set shortages, and distributor underperformance. Global Limb Reconstruction was a relative bright spot, rising 8.5%, while Bone Growth Therapies grew 4.5%.

The combined shortfalls pushed management to cut its full-year outlook. Net sales guidance was lowered to $825 million to $830 million from a prior range of $845 million to $855 million, and non-GAAP adjusted EBITDA guidance was trimmed to $86 million to $88 million from $95 million to $98 million. CEO Massimo Calafiore said the revised guidance reflects both third-quarter performance and the near-term impact of accelerated actions to restructure U.S. Spine commercial execution.

To stabilize the Spine business, the company is concentrating resources on its highest-performing distributor partners and working to improve instrument-set supply and allocation. Those moves are setting the stage for the planned U.S. full commercial launch of the VIRATA Spinal Fixation System later in the fourth quarter of 2026. Calafiore acknowledged the restructuring actions carry near-term disruption risk but said they are intended to build a stronger foundation for sustainable growth, profitability, and cash generation.

For a company with a $318 million market cap, the shift from an expected profit to a reported loss is the number that most reframes the investment case. Nine-month free cash flow stood at negative $61.3 million, and rising total liabilities add to the pressure. The Q4 VIRATA launch is now the clearest near-term catalyst investors will be watching to gauge whether the U.S. Spine segment can begin to recover.